Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
作者信息
Solipuram Vinod, Baretti Marina, Kim Alexander Y, Chen Lucy X, Fahrner Jill A, Gunay-Aygun Meral, Peng Xiao P, Hardenbergh Dylan, Ferguson Anna, Griffith Paige, Wang Yuxuan, Brancati Madelena, Gopalakrishna Harish, Kato Tomoaki, Shubert Chris, Laheru Daniel, Yarchoan Mark
机构信息
Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
出版信息
Hepatology. 2021 Nov;74(5):2899-2901. doi: 10.1002/hep.31998. Epub 2021 Aug 21.
Abstract
摘要
相似文献
1
Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
Hepatology. 2021 Nov;74(5):2899-2901. doi: 10.1002/hep.31998. Epub 2021 Aug 21.
2
Curative Treatment of Ornithine Transcarbamylase Deficiency With a Liver Transplant: A Case Report.
Exp Clin Transplant. 2019 Feb;17(1):119-120. doi: 10.6002/ect.2016.0052. Epub 2016 Jul 22.
3
Hyperammonemic Encephalopathy Exacerbated by Parenteral Nutrition in Fibrolamellar Hepatocellular Carcinoma.
Am J Med. 2020 Dec;133(12):e745-e746. doi: 10.1016/j.amjmed.2020.06.022. Epub 2020 Jul 31.
4
Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.
South Med J. 2008 May;101(5):543-5. doi: 10.1097/SMJ.0b013e31816bf5cc.
5
[Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma].
Medicina (B Aires). 2012;72(5):425-7.
6
A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.
Am J Case Rep. 2017 Mar 8;18:234-241. doi: 10.12659/ajcr.901682.
7
Acute hyperammonemic encephalopathy due to a portosystemic shunt in a non-cirrhotic adult patient.
J Crit Care. 2019 Oct;53:59-61. doi: 10.1016/j.jcrc.2019.05.015. Epub 2019 May 28.
8
Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
Am J Med Sci. 2009 Dec;338(6):522-4. doi: 10.1097/MAJ.0b013e3181bccfb4.
9
Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Anticancer Res. 2020 Sep;40(9):5271-5276. doi: 10.21873/anticanres.14531.
10
Hepatic encephalopathy and orotic aciduria associated with hepatocellular carcinoma in a noncirrhotic liver.
Hepatology. 1988 Jan-Feb;8(1):78-81. doi: 10.1002/hep.1840080116.
引用本文的文献
1
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma.
Sci Adv. 2023 Jun 23;9(25):eadg7038. doi: 10.1126/sciadv.adg7038. Epub 2023 Jun 21.
2
Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver.
J Hepatocell Carcinoma. 2023 May 15;10:745-752. doi: 10.2147/JHC.S406902. eCollection 2023.
3
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
NPJ Precis Oncol. 2023 Mar 23;7(1):29. doi: 10.1038/s41698-023-00371-2.
4
A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.
Onco Targets Ther. 2022 Oct 3;15:1095-1103. doi: 10.2147/OTT.S296127. eCollection 2022.
5
Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.
Front Oncol. 2022 Apr 8;12:864106. doi: 10.3389/fonc.2022.864106. eCollection 2022.
本文引用的文献
1
Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.
J Gastrointest Oncol. 2019 Jun;10(3):582-588. doi: 10.21037/jgo.2019.01.28.
2
A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.
Am J Case Rep. 2017 Mar 8;18:234-241. doi: 10.12659/ajcr.901682.
Zotero 插件